pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.
Company profile
Ticker
PAVM
Exchange
Website
CEO
Lishan Aklog
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PAXmed Inc.
SEC CIK
Corporate docs
Subsidiaries
(PAVmed Inc. • Lucid Diagnostics Inc. • LucidDx Labs Inc. • Veris Health Inc. • Oncodisc Inc • CapNostics LLC ...
PAVM stock data
Latest filings (excl ownership)
8-K
Parties to implement a pilot program of the Veris Cancer Care Platform
30 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Entry into a Material Definitive Agreement
26 Apr 24
10-K
2023 FY
Annual report
25 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 24
Transcripts
PAVM
Earnings call transcript
2023 Q4
27 Mar 24
PAVM
Earnings call transcript
2023 Q3
15 Nov 23
PAVM
Earnings call transcript
2023 Q2
16 Aug 23
PAVM
Earnings call transcript
2023 Q1
17 May 23
PAVM
Earnings call transcript
2022 Q4
15 Mar 23
PAVM
Earnings call transcript
2022 Q3
16 Nov 22
PAVM
Earnings call transcript
2022 Q2
17 Aug 22
PAVM
Earnings call transcript
2022 Q1
13 May 22
PAVM
Earnings call transcript
2021 Q4
29 Mar 22
PAVM
Earnings call transcript
2021 Q3
17 Nov 21
Latest ownership filings
4
Timothy E Baxter
23 Feb 24
4
Debra White
23 Feb 24
4
Ronald M Sparks
23 Feb 24
4
Joan B Harvey
23 Feb 24
4
Michael J Glennon
23 Feb 24
4
James L Cox
23 Feb 24
4
Lucid Diagnostics Inc.
20 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
20 Feb 24
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm |
Cash burn (monthly) | 3.59 mm | 2.53 mm | 7.25 mm | 7.20 mm | 3.70 mm | 4.75 mm |
Cash used (since last report) | 25.72 mm | 18.16 mm | 52.01 mm | 51.67 mm | 26.52 mm | 34.07 mm |
Cash remaining | 690.85 k | 8.25 mm | -25.60 mm | -25.26 mm | -107.80 k | -7.66 mm |
Runway (months of cash) | 0.2 | 3.3 | -3.5 | -3.5 | -0.0 | -1.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 15 |
Closed positions | 3 |
Increased positions | 12 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 3.62 bn |
Total shares | 12.49 mm |
Total puts | 0.00 |
Total calls | 126.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 3.81 mm | $1.12 bn |
Ayrton Capital | 2.24 mm | $661.15 mm |
BLK Blackrock | 1.12 mm | $331.06 mm |
First Manhattan | 1.00 mm | $294.60 mm |
Geode Capital Management | 826.09 k | $243.44 mm |
Valeo Financial Advisors | 322.27 k | $94.94 mm |
WFC Wells Fargo & Co. | 301.60 k | $88.85 mm |
STT State Street | 281.39 k | $82.90 mm |
XML Financial | 154.99 k | $45.66 mm |
Levin Capital Strategies | 149.75 k | $44.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 24 | PAVmed | Common Stock | Other | Acquire J | No | No | 1.4033 | 3,331,771 | 4.68 mm | 34,634,191 |
30 Jan 23 | Joan B Harvey | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Timothy E Baxter | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Glennon Michael J | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Debra White | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
News
Lucid Diagnostics Announces Peer-Reviewed Publication Of Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study Of EsoGuard Esophageal Precancer Testing
2 May 24
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Mar 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
Press releases
PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024
3 May 24
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024
2 May 24
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
2 May 24
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month
29 Apr 24
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
8 Apr 24